Latest Advencement Of Dealing With Psoristic Arthritis

Investigators who are monitoring the continuing IMPACT (Infliximab Multinational Psoriatic Arthritis Controlled Trial) of infliximab (Remicade®) in psoriatic arthritis (PsA) patients are now so bullish about the success of the treatment that they plan to publish the first-ever guidelines on what constitutes remission in the formerly incurable disease. Long-term data show inhibition of structural damage and sustained improvement in functional status and quality of life. New data, including two-year treatment duration, show a significantly higher proportion of patients with active psoriatic arthritis receiving REMICADE (infliximab) achieved and sustained a high degree of clinical improvement in arthritis, as assessed using the rheumatoid arthritis (RA) definition for "major clinical response," compared with patients receiving placebo. There has been some evidence to support a role for immunological factors in the development of Psoriatic Arthritis.